Patient metabolic profile defined by liver and muscle 18F-FDG PET avidity is independently associated with overall survival in gastric cancer
ConclusionsElevated LRF ratio, a patient-specific PET –CT-based metabolic parameter, was independently associated with an improvement in OS in patients with metastatic gastric cancer. With prospective validation, LRF ratio may be a useful, host-specific metabolic parameter for prognostication in gastric cancer. (Source: Gastric Cancer)
Source: Gastric Cancer - March 4, 2024 Category: Gastroenterology Source Type: research
Racial disparities of gastric cancer in the USA: an overview of epidemiology, global screening guidelines, and targeted screening in a heterogeneous population
This article aims to provide context to gastric cancer epidemiology globally, review risk factors for developing gastric cancer, highlight racial and ethnic disparities in gastric cancer burden in the USA, examine current guidelines that exist in high incidence countries, and suggest future studies examining the efficacy of additional screening in high-risk populations to reduce gastric cancer mortality and disparate burden on ethnic minorities in the USA. (Source: Gastric Cancer)
Source: Gastric Cancer - March 4, 2024 Category: Gastroenterology Source Type: research
Statin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma: a Swedish population-based cohort study
ConclusionsPerioperative use of statins does not seem to improve the 5-year survival in patients who undergo gastrectomy with curative intent for gastric adenocarcinoma in Sweden. (Source: Gastric Cancer)
Source: Gastric Cancer - March 2, 2024 Category: Gastroenterology Source Type: research
Discrepant effect of high-density lipoprotein cholesterol on esophageal and gastric cancer risk in a nationwide cohort
ConclusionsLow HDL-C increased the risk of gastric cancer, wherein high HDL-C was associated with esophageal cancer risk with discrepancies by sex and smoking status. (Source: Gastric Cancer)
Source: Gastric Cancer - February 28, 2024 Category: Gastroenterology Source Type: research
Gastric fundic gland polyposis and cancer development after eradication of Helicobacter pylori in patient with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)
AbstractA 44-year-old woman with gastric cancer (GC) and fundic gland polyposis (FGPs) was referred to our hospital for further diagnosis and treatment. She successfully underwent eradication therapy for Helicobacter pylori (HP) 6 years ago, but did not exhibit FGPs at that time. When she underwent an esophagogastroduodenoscopy 2, 4, and 5 years after the eradication of HP, her imaging results revealed the existence of FGPs which gradually increased in her gastric fundus and body. Gastric adenocarcinoma and proximal polypo sis of the stomach (GAPPS) was suspected and a mutational analysis was performed, revealing anAPC ...
Source: Gastric Cancer - February 26, 2024 Category: Gastroenterology Source Type: research
Impact of preoperative prealbumin levels on long-term prognosis in patients with gastric cancer after gastrectomy: a retrospective cohort study
ConclusionsPreoperative prealbumin levels correlated with OS in patients with gastric cancer after gastrectomy; the lower the prealbumin level, the worse is the prognosis. Prealbumin levels may be associated with other-cause survival. (Source: Gastric Cancer)
Source: Gastric Cancer - February 24, 2024 Category: Gastroenterology Source Type: research
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023
(Source: Gastric Cancer)
Source: Gastric Cancer - February 22, 2024 Category: Gastroenterology Source Type: research
Killer cell lectin-like receptor G2 facilitates aggressive phenotypes of gastric cancer cells via dual activation of the ERK1/2 and JAK/STAT pathways
ConclusionsKLRG2 knockdown attenuated the malignant phenotypes of GC cells via downregulation of JAK/STAT and MAPK-ERK1/2 pathway activity and upregulation of p38 MAPK and p53. Targeted suppression of KLRG2 may serve as a new treatment approach for GC. (Source: Gastric Cancer)
Source: Gastric Cancer - February 22, 2024 Category: Gastroenterology Source Type: research
Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer
ConclusionIn summary, our research reveals the molecular mechanisms of irreversible HER2-TKIs in regulating HER2 protein expression by promoting HER2 internalization. These findings advance our comprehension of targeted therapy for GC and provide a promising therapeutic combination strategy with enhanced efficacy against HER2-positive GC. (Source: Gastric Cancer)
Source: Gastric Cancer - February 22, 2024 Category: Gastroenterology Source Type: research
Long-term oncological outcomes of 3D versus 2D laparoscopic gastrectomy for gastric cancer: a randomized clinical trial
ConclusionsFor patients with locally resectable GC, 3D-LG performed by experienced surgeons in high-volume professional institutions can achieve long-term oncological outcomes comparable to those of 2D-LG.Registration numberNCT02327481 (http://clinicaltrials.gov).Graphical abstract (Source: Gastric Cancer)
Source: Gastric Cancer - February 20, 2024 Category: Gastroenterology Source Type: research
Nishi memorial award in gastric cancer
(Source: Gastric Cancer)
Source: Gastric Cancer - February 14, 2024 Category: Gastroenterology Source Type: research
Sustained exposure to Helicobacter pylori induces immune tolerance by desensitizing TLR6
AbstractHelicobacter pylori (H. pylori, Hp) has been designated a class I carcinogen and is closely associated with severe gastric diseases. During colonization in the gastric mucosa,H. pylori develops immune escape by inducing host immune tolerance. The gastric epithelium acts as the first line of defense againstH. pylori, with Toll-like receptors (TLRs) in gastric epithelial cells being sensitive toH. pylori components and subsequently activating the innate immune system. However, the mechanism of immune tolerance induced byH. pylori through the TLR signalling pathway has not been fully elucidated. In this research, we d...
Source: Gastric Cancer - February 4, 2024 Category: Gastroenterology Source Type: research
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial
ConclusionsIn FGFR2b-positive advanced GC, the combination of bemarituzumab-mFOLFOX6 led to numerically longer median PFS and OS compared with mFOLFOX6 alone. Efficacy was more pronounced with FGFR2b overexpression in ≥ 10% of tumor cells. Confirmatory phase 3 trials are ongoing (NCT05052801, NCT05111626).Clinical trial registrationNCT03694522. (Source: Gastric Cancer)
Source: Gastric Cancer - February 3, 2024 Category: Gastroenterology Source Type: research
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial
ConclusionsThis study did not meet its primary OS endpoint. Compared to placebo, rivoceranib improved PFS, ORR, and DCR. Rivoceranib also improved OS in a prespecified patient subgroup receiving ≥4th-line therapy. (Source: Gastric Cancer)
Source: Gastric Cancer - January 28, 2024 Category: Gastroenterology Source Type: research
Inhibition of proprotein convertases activity results in repressed stemness and invasiveness of cancer stem cells in gastric cancer
ConclusionsPCs are overexpressed in GC and associated with poor prognosis. PCs are involved in the malignant and metastatic potential of CSCs via the regulation of EMT, the YAP/TAZ/TEAD oncogenic pathway, and their stemness and invasive properties. Their repression represents a new strategy to target CSCs and impair metastatic spreading in GC. (Source: Gastric Cancer)
Source: Gastric Cancer - January 27, 2024 Category: Gastroenterology Source Type: research
